PharmaCyte Biotech financials
$0.4190−0.21%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Apr 30 | FY25 Apr 30 | FY24 Apr 30 | FY23 Apr 30 | FY22 Apr 30 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$6.9M | -$4.4M | -$8.5M | -$6.5M | -$4.4M |
| Net income | -$23.2M | $23.4M | -$17.2M | -$4.3M | -$4.2M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 |
| EBITDA | -$5.3M | -$4.4M | -$6.5M | -$6.5M | -$3.6M |
| Operating cash flow | -$5.2M | -$3.0M | -$2.2M | -$3.8M | -$4.1M |
| Free cash flow | -$5.2M | -$3.0M | -$2.2M | -$3.8M | — |
| Diluted shares | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M |
Balance sheet
| Period end | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $18.6M | $15.2M | $50.2M | $68.0M | $85.4M |
| Short-term investments | $18.5M | $366.3K | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $46.8M | $55.2M | $59.9M | $73.3M | $90.6M |
| Total liabilities | $11.8M | $3.3M | $20.4M | $586.6K | $704.4K |
| Shareholders' equity | $33.3M | $51.9M | $39.5M | $72.7M | $89.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology